Scott Dreyer - Dec 8, 2025 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Role
EVP & Chief Commercial Officer
Signature
/s/ Colleen Tupper as Attorney-In-Fact For Scott Dreyer
Stock symbol
COLL
Transactions as of
Dec 8, 2025
Transactions value $
-$568,015
Form type
4
Date filed
12/10/2025, 04:32 PM
Previous filing
Aug 20, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dreyer Scott EVP & Chief Commercial Officer C/O COLLEGIUM PHARMACEUTICAL, INC., 100 TECHNOLOGY CENTER DRIVE, STOUGHTON /s/ Colleen Tupper as Attorney-In-Fact For Scott Dreyer 2025-12-10 0001746251

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COLL Common Stock Options Exercise $280K +17.6K +16.99% $15.90 121K Dec 8, 2025 Direct F1
transaction COLL Common Stock Sale -$533K -11.1K -9.18% $47.89 110K Dec 8, 2025 Direct F1, F2
transaction COLL Common Stock Sale -$315K -6.48K -5.88% $48.66 104K Dec 8, 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COLL Stock Option (Right to Purchase) Options Exercise $0 -17.6K -100% $0.00 0 Dec 8, 2025 Common Stock 17.6K $15.90 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2025.
F2 The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.212 to $48.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.215 to $49.08, inclusive.
F4 The option is fully vested and exercisable.